NCT07470840 2026-03-24
SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma
Fujian Cancer Hospital
Phase 2 Not yet recruiting
Clinical Trials
15 trialsNCT05052801 2026-02-19
FORTITUDE-101
Amgen
Phase 3 Active not recruiting
NCT05325866 2026-02-04
FORTITUDE-301
Amgen
Phase 1/2 Completed
NCT06967987 2026-01-21
BEMAFLOT
Institut Cancerologie de l'Ouest
Phase 2 Withdrawn
NCT05111626 2025-12-15
FORTITUDE-102
Amgen
Phase 3 Active not recruiting
NCT05322577 2025-12-05
FORTITUDE-103
Amgen
Phase 1/2 Active not recruiting
NCT07146919 2025-08-28
ANGELICA
Centre Leon Berard
Phase 1/2 Not yet recruiting
NCT06978062 2025-06-05
NeoBEMA
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Not yet recruiting
NCT05267470 2025-03-25
FORTITUDE-201
Amgen
Phase 1 Terminated
NCT02318329 2024-06-04
Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT03343301 2024-02-28
FIGHT
Five Prime Therapeutics, Inc.
Phase 1 Completed
NCT03694522 2024-02-28
FIGHT
Five Prime Therapeutics, Inc.
Phase 2 Completed
NCT05913115 2023-06-22
A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer
Amgen
Phase 1 Completed
NCT03801278 2021-12-13
FPA144
Five Prime Therapeutics, Inc.
No longer available
NCT02213289 2021-04-08
PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression
University of Chicago
Phase 2 Completed